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Abstract
Objective: To describe the most prevalent pediatric hereditary autoinflammatory syndromes.
Sources: A review of the literature including relevant references from the PubMed and SciELO was carried out 
using the keywords autoinflammatory syndromes and child.
Summary of the findings: The hereditary autoinflammatory syndromes are caused by monogenic defects of 
innate immunity and are classified as primary immunodeficiencies. These syndromes are characterized by recurrent 
or persistent systemic inflammatory symptoms and must be distinguished from infectious diseases, autoimmune 
diseases, and other primary immunodeficiencies. This review describes the epidemiological, clinical and laboratory 
features, prognosis, and treatment of the main autoinflammatory syndromes, namely: familial Mediterranean 
fever; TNF receptor associated periodic syndrome; the cryopyrinopathies; mevalonate kinase deficiency; pediatric 
granulomatous arthritis; pyogenic arthritis, pyoderma gangrenosum and acne syndrome; Majeed syndrome; and 
deficiency of interleukin 1 receptor antagonist. The cryopyrinopathies discussed include neonatal-onset multisystem 
inflammatory disease (also known as chronic infantile neurologic, cutaneous and articular syndrome) Muckle-Wells 
syndrome, and familial cold autoinflammatory syndrome.
Conclusions: Pediatricians must recognize the clinical features of the most prevalent autoinflammatory 
syndromes. Early referral to a pediatric rheumatologist may allow early diagnosis and institution of treatment, 
with improvement in the quality of life of these patients.
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Introduction
Over the past 12 years, the clinical and pathophysiological 
features of the pediatric autoinflammatory syndromes 
(AIS) have been the subject of intense research and 
broad recognition.1,2 The milestone event that marked the 
beginning of this new era of discovery on the pathophysiology 
of autoinflammatory diseases was the 1997 description of 
the underlying genetic cause of familial Mediterranean fever 
(FFM), the most prevalent AIS.3,4
354  Jornal de Pediatria - Vol. 86, No. 5, 2010
The autoinflammatory syndromes are caused by 
monogenic defects of innate immunity and are classified 
as primary immunodeficiencies.5 The clinical picture of 
these syndromes is characterized by recurrent or persistent 
inflammatory symptoms affecting various organs and body 
systems, and the AIS must be distinguished from infectious 
diseases, autoimmune conditions, and other primary 
immunodeficiencies.6 Unlike in pediatric autoimmune 
conditions such as juvenile idiopathic arthritis (JIA), juvenile 
systemic lupus erythematosus, or juvenile dermatomyositis, 
self-reactive T cells or high circulating autoantibody titers 
are not found in the AIS spectrum. Hence, the conditions 
in this group were termed “autoinflammatory.”7,8
In the vast majority of cases, the symptoms of 
autoinflammatory syndromes arise in childhood.8 Recurrent 
fever is the most prevalent manifestation, and is accompanied 
by other signs and symptoms of inflammation, particularly 
affecting the skin, eyes, bones, joints, gastrointestinal 
tract, CNS, and serous membranes.6-9 Fever may recur in 
precise or irregular intervals, or, in rare cases, may even 
be continuous.10
Due to the importance of fever in diagnosing AIS, they 
are also known as periodic fever syndromes.6 The presence 
of fever is not, however, indispensable for establishing a 
diagnosis; in some syndromes, such as the pyogenic AIS, 
fever is actually rare or altogether absent.7
This review seeks to describe the main autoinflammatory 
syndromes and their epidemiologic features, clinical 
manifestations, associated laboratory changes, prognosis, 
and management.
Sources
A literature search was performed in the PubMed and 
SciELO databases using the keywords “autoinflammatory 
syndromes” and “child.” Relevant references were used to 
construct a review of the literature.
Summary of findings
The present article addresses the following syndromes: 
FMF; TNF receptor associated periodic syndrome (TRAPS); 
the cryopyrinopathies; mevalonate kinase deficiency 
(MKD); pediatric granulomatous arthritis (PGA); pyogenic 
arthritis, pyoderma gangrenosum and acne (PAPA); 
Majeed syndrome; and deficiency of interleukin 1 receptor 
antagonist (DIRA).
The clinical spectrum of cryopyrinopathy includes 
neonatal-onset multisystem inflammatory disease (NOMID, 
also known as chronic infantile neurologic, cutaneous and 
articular syndrome or CINCA syndrome), Muckle-Wells 
syndrome (MWS), and familial cold autoinflammatory 
syndrome (FCAS).
Table 1 lists the main features useful in distinguishing 
the various monogenic autoinflammatory syndromes.
Familial Mediterranean fever (FMF)
FMF is the most prevalent autoinflammatory syndrome, 
affecting more than 100,000 individuals worldwide.11,12 
The first case description of FMF was published in 1908 
by Janeway & Mosenthal,13 and the first case series was 
reported by Siegal in 1945.14 FMF chiefly affects people of 
eastern Mediterranean descent (Sephardi Jewish, Armenian, 
Turkish, and Arab populations); the prevalence of FMF in 
this region ranges from 1 in 200 to 1 in 1,000. Both genders 
are affected equally, although some studies have suggested 
slight male predominance.15-17
The gene associated with FMF, the Mediterranean fever 
gene (MEFV), was isolated in 1997, and is located on the 
short arm of chromosome 16 (locus 16p13).3,4 FMF [Online 
Mendelian Inheritance in Man (OMIM) accession no. 249100] 
follows an autosomal recessive pattern of inheritance; thus 
far, at least 188 pathogenic mutations have been described, 
most of which are found within exons 2 and 10 of MEFV.18 
MEFV codes for a 781-amino acid-long protein known as 
pyrin or marenostrin.3,4 The five most common mutations 
in individuals affected by FMF are M694V, M680I, M694I, 
E148Q, and E726A.3,15,19
The pathophysiology of FMF has yet to be fully elucidated, 
but several studies have suggested that pyrin plays a role in 
modulating production of interleukin 1-beta (IL-1β), a major 
proinflammatory cytokine.16,20,21 Pyrin, alongside cryopyrin, 
ASC, and caspase-1, is one of the constituents of a protein 
complex known as the inflammasome.22 The inflammasome 
regulates the rate of production of active IL1-β from its 
inactive precursor, pro-IL-1β.23,24 Pyrin mutations are 
believed to lead to increased inflammasome activation with 
excess IL-1β release, which would consequently produce 
the systemic inflammatory symptoms of FMF.23
The clinical manifestations of FMF arise before the 
age of 30 in the overwhelming majority of patients.16 The 
disease is characterized by recurrent fever associated with 
abdominal or chest pain (due to serositis) and arthritis of 
the large joints.7 Episodes last 1 to 4 days and occur with 
varying regularity, usually from one per week to one every 
4 months; in rare cases, attacks occur no more than once 
a year.11 Patients present with sudden onset of high fever 
(38.5-40 °C), which resolves spontaneously within 6 to 96 
hours, accompanied by malaise and incapacitating pain. 
The intercritical periods are asymptomatic.7,8,23
Other than fever, abdominal pain is the most frequent 
manifestation of FMF (95%)8. Pain is due to generalized 
acute peritonitis, is moderate to severe in intensity and 
characterized by sudden onset.25 It is most severe in the 
first 6 to 20 hours of each attack, and subsides within 24 
to 48 hours.25 Abdominal examination reveals guarding, 
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    Duration Most specific clinical Amyloidosis
Condition Gene Inheritance Protein of fever manifestations rate Treatment
FMF MEFV AR Pyrin 1-3 days Peritonitis, pleuritis,  13% Colchicine
     erysipelas-like rash, 
     large-joint arthritis
TRAPS TNFRSF1A AD TNF  7-14 days Abdominal pain, localized 14% (64% when Etanercept,
   receptor   myalgias and erythema, cysteine mutations anakinra
   p55  periorbital edema are present)
 
FCAS CIAS1 AD Cryopyrin 6-24 hours Symptoms triggered  2% Anakinra, 
     by cold  rilonacept
MWS CIAS1 AD Cryopyrin 1-2 days Sensorineural  25-33% Anakinra, 
     hearing loss  canakinumab
NOMID CIAS1 AD Cryopyrin Continuous Developmental delay, Higher risk Anakinra,
     aseptic meningitis,   thalidomide
     papilledema, 
     epiphyseal overgrowth, 
     distinctive facial appearance 
MKD MVK AR Mevalonate 3-7 days Abdominal pain, diarrhea, Three  Simvastatin,
   kinase  vomiting, bilateral cervical  reported etanercept,
     lymphadenopathy,  cases
     elevated IgD and urinary 
     mevalonate levels
AGP NOD2 AD NOD2 Not common Chronic granulomatous  No reports NSAIDs,
     arthritis, uveitis, rash  corticosteroids, 
       methotrexate, 
       ciclosporin, 
       etanercept, 
       infliximab and 
       adalimumab
PAPA PSTPIP1 AD PSTPIP1 Not common Pyoderma gangrenosum,  No reports NSAIDs, 
     pyogenic aseptic arthritis,   corticosteroids
     acne
Majeed LPIN2 AR LIPIN2 Not common Neutrophilic dermatitis,  No reports NSAIDs, 
     chronic recurrent multifocal   corticosteroids, 
     osteomyelitis,   interferon alpha
     dyserythropoietic anemia  or gamma,
       bisphosphonates,
       anti-TNF agents
DIRA IL1RN AR ILRa Not common Neonatal onset, pustular  No reports Anakinra
     dermatitis, chronic recurrent 
     multifocal osteomyelitis
Table 1 - Main features of the hereditary autoinflammatory syndromes
AD = autosomal dominant; AR = autosomal recessive; DIRA = deficiency of interleukin-1 receptor antagonist; FCAS = familial cold autoinflammatory syndrome; 
FMF = familial Mediterranean fever; MKD = mevalonate kinase deficiency; MWS = Muckle-Wells syndrome; NOMID = neonatal-onset multisystem inflammatory disease; 
NSAID = non-steroidal anti-inflammatory drug; PAPA = pyogenic arthritis, pyoderma gangrenosum and acne; PGA = pediatric granulomatous arthritis; TNF = tumor 
necrosis factor; TRAPS = TNF receptor associated periodic syndrome.
rebound tenderness, and abdominal distension, and may 
mimic surgical acute abdomen8,16,25. Around 30 to 40% 
of FMF patients are estimated to undergo unnecessary 
appendectomy or cholecystectomy.16 Other gastrointestinal 
symptoms include constipation and, less commonly, 
diarrhea.17,25
Acute arthritis may occur in 54 to 75% of patients.26 
Attacks last approximately 1 week, and are often 
monoarticular, affecting the large joints of the lower 
limbs.16 Joint involvement may occur spontaneously or be 
preceded by trauma or prolonged exertion.16,26 Roughly 
5% of patients may have chronic arthritis of the hip, knee, 
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ankle, or (rarely) temporomandibular joint, mimicking the 
systemic form of juvenile idiopathic arthritis.27 Another 
musculoskeletal symptom is myalgia, which occurs in 10% 
of patients, usually affects the calves and is triggered by 
physical activity.7,16,28 FMF may also present as “protracted 
febrile myalgia,” which is characterized by severe bilateral 
lower extremity pain, prolonged fever, and abdominal pain. 
Each episode may last up to 6 weeks.29
Recurrent pleurisy as a cause of chest pain is reported 
in 39% of patients, whereas pericarditis is rare (1 to 2.4% 
of cases).27,30 The most common and specific cutaneous 
manifestation of FMF is erysipelas-like erythema, which 
occurs in 7 to 40% of cases16,19 and is characterized by 
erythematous, vesicular, and bullous lesions mostly affecting 
the lower extremities.16 These lesions may persist for 
24 to 48 hours, and the attending signs of inflammation 
are often misdiagnosed as cellulitis, prompting antibiotic 
therapy.16,19
The diagnosis of FMF is based on clinical criteria, family 
history, exclusion of other periodic fever syndromes, and 
a clinical response to colchicine. In 1997, Livneh et al. 
proposed a set of diagnostic criteria for FMF.31 These 
criteria have been validated for pediatric use, with 98.8% 
sensitivity and 54.6% specificity for diagnosing FMF in 
children and adolescents. The same group of researchers 
has since proposed a new set of highly sensitive (86.5%) 
and specific (93.6%) diagnostic criteria.32
Laboratory testing may reveal leukocytosis and elevated 
acute phase reactants, such as erythrocyte sedimentation 
rate (ESR), C-reactive protein (CRP), and serum amyloid A 
(SAA); the latter is considered the best laboratory marker of 
subclinical inflammation.8,16,33 Definitive diagnosis requires 
a finding of MEFV mutations.6,7
The main complication of FMF is secondary AA-type 
amyloidosis, which occurs in up to 13% of patients. 
The kidneys are most affected, usually by worsening 
proteinuria that progresses to nephrotic syndrome and, 
occasionally, chronic renal failure.8,17,34 FMF patients 
should be systematically tested for proteinuria every 3 to 
6 months.
Colchicine is still the most effective treatment; it can 
induce complete remission or reduction in frequency, 
duration, and severity of attacks in most FMF patients.35 
Colchicine is also useful in preventing, slowing the 
progression of or even reverting renal amyloidosis.17,36 The 
recommended dose is 0.03 mg/kg/day, which can be carefully 
increased up to 3.0 mg/day in the 5 to 10% of patients that 
are unresponsive to this initial dosage.16 Colchicine therapy 
is relatively safe, even during pregnancy. The most common 
adverse effects are diarrhea and abdominal pain; rarely, 
rash, hair loss, leukopenia, thrombocytopenia, neuropathy, 
myopathy, liver injury, and impaired spermatogenesis 
may occur.35-37 In patients unresponsive to or unable to 
tolerate colchicine, treatment with interferon gamma38 and 
combination therapy with thalidomide39 have been reported. 
More recently, immunobiologics such as the IL-1 receptor 
antagonist anakinra and the anti-TNF agents etanercept 
and infliximab have also been used in refractory cases, 
with encouraging results.15,40
TNF receptor associated periodic syndrome 
(TRAPS)
TRAPS (OMIM accession no. 142680) is the second 
most prevalent of the autoinflammatory syndromes, and 
its underlying genetic defect was described in 1999.41 It is 
caused by mutations in the TNFRSF1A gene and inherited in 
an autosomal dominant pattern.41 This gene, which codes 
for the p55 TNF receptor (TNFR1), has 10 exons and is 
located on the short arm of chromosome 12.41 Thus far, 
93 TRAPS-related mutations have been described, mostly 
in exons 2, 3, 4, and 6, and also in intron 4.18 Mutations 
involving the cysteine residues of the extracellular portion 
of the receptor are associated with increased severity and 
amyloidosis risk.21,41
The TNFR1 receptor is an important mediator of TNF-
alpha signaling; this cytokine plays an essential role in the 
inflammatory response. The pathophysiology of TRAPS 
is believed to involve multiple factors.42 Some affected 
individuals have decreased shedding of the mutant receptor 
from the cell surface. Receptor shedding is believed to be 
necessary for blocking TNF-alpha activity and preventing 
exacerbated inflammatory response.42,43 Additional studies 
have suggested that the mutated receptor has defective 
intracellular trafficking; it is retained in the endoplasmic 
reticulum. This intracellular buildup of the receptor could 
lead to spontaneous activation, triggering an inflammatory 
response.44,45 Another pathophysiological mechanism is a 
defect in neutrophil apoptosis that occurs in some patients 
with TRAPS and is believed to possibly perpetuate the 
inflammatory response.45,46
The clinical manifestations of TRAPS usually arise in 
childhood or adolescence (mean age, 10 years; range, 
1 to 63 years).6,7 Duration of fever is longer than in any 
other AIS: 14 days on average, ranging from 2 to 56 days. 
The intercritical period (months to years) and severity 
are highly variable.47 Fever is most often accompanied by 
severe, sudden-onset abdominal pain (77%), which leads 
to negative laparotomy in 33% of patients.6,21
The second most common symptom is localized, 
migratory muscle pain, which occurs in 64% of patients.48 
This myalgia is characterized by pain and erythematous rash 
overlying the affected area, and is caused by a monocytic 
fasciitis which can be detected on biopsy and MRI.48 Roughly 
half of all patients have erythematous macules or, more 
rarely, edematous, urticaria-like plaques over myalgic 
areas.21,43 Less commonly, the rash is disseminated and 
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Figure 1 - Conjunctivitis and eyelid edema in a patient with TNF 
receptor associated periodic syndrome (TRAPS)
takes on a serpiginous or reticular appearance.47 Ocular 
manifestations are frequent (49% of cases) and may include 
conjunctivitis and uveitis, with periorbital pain, erythema, 
and/or edema.6,47  Figure 1 shows conjunctivitis and eyelid 
edema in a patient with TRAPS.
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treatment of choice for TRAPS.43 Etanercept significantly 
reduces the number and severity of episodes, although its 
efficacy may decrease with prolonged use.55 Successful 
use of IL-1 receptor antagonist (anakinra) in etanercept-
refractory cases has been reported.56-58 The use of infliximab, 
another anti-TNF biologic, should not be encouraged, as 
induction of proinflammatory activity has been reported in 
some patients with TRAPS.59 The management of TRAPS 
may also include corticosteroid therapy during flares, but 
chronic corticosteroid therapy does not prevent or blunt 
the severity of later attacks.6,7 Unlike in FMF, colchicine 
is of limited efficacy in TRAPS; less than 22% of patients 
are responsive.2,43 Non-steroidal anti-inflammatory drugs 
(NSAIDs) usually offer no relief beyond suppression of 
fever.6,7
Cryopyrin-associated periodic syndrome (CAPS) or 
cryopyrinopathies
The cryopyrin-associated periodic syndrome spectrum, 
which encompass FCAS, MWS, and NOMID (CINCA 
syndrome), is caused by mutations in the cold induced 
autoinflammatory syndrome 1 (CIAS1) gene, first identified 
in 2001.60 CIAS1 codes for the protein cryopyrin, also 
known as NALP3 or PYPAF1.61 The cryopyrinopathies are 
transmitted in an autosomal dominant pattern, and, thus 
far, 118 CAPS-associated mutations have been described.18 
The CIAS1 gene is located on chromosome 1q44 and has 
9 exons.60 Roughly 85% of CIAS1 mutations occur in 
exon 3.62,63 Cryopyrin is one of the constituents of the 
inflammasome, which plays a key role in the regulation 
of intracellular defense in response to bacterial toxins and 
compounds released during cell injury or stress.22,64,65 
This protein is essential for activation of caspase-1, the 
enzyme that cleaves pro-IL1-β into its active form, IL1-
beta, which in turn is a major proinflammatory cytokine.66 
In healthy individuals, activation of the inflammasome is 
inhibited by an interaction between distinct portions of 
the cryopyrin molecule itself.42 CIAS1 mutations lead to 
a disruption of this inactive conformation of cryopyrin, 
leading to activation of the inflammasome, increasing 
IL1-beta secretion and triggering systemic inflammatory 
symptoms.66-68
Clinical manifestations vary among the three 
cryopyrinopathies, but several common features are often 
found, such as fever, pseudourticarial rash, joint involvement, 
and profoundly elevated inflammatory markers.7,61 The 
most consistent finding across the CAPS spectrum is 
a migratory, maculopapular, urticaria-like, and usually 
nonpruritic rash.61,69 Skin biopsy reveals polymorphonuclear 
perivascular infiltration of the dermis, which contrasts with 
the biopsy findings of classical urticaria.61,70 The unique 
features of each of the cryopyrinopathies are described 
below.
Other common symptoms include arthralgia or arthritis 
(51%), pleurisy (32%), and headache (68%).47 Various 
central nervous system (CNS) manifestations have also been 
reported, such as meningitis, optic neuritis, and behavioral 
changes.49 Sporadic reports of scrotal pain, pericarditis, 
pharyngitis, and cervical lymphadenopathy have been 
published.8 In addition, three cases of TRAPS with no fever 
were recently published.50,51
Laboratory testing during attacks may reveal increased 
levels of inflammatory markers, such as ESR, CRP, and SAA, 
as well as moderate leukocytosis and thrombocytosis.8 
Depending on disease severity, inflammatory markers may 
remain elevated even in the afebrile intercritical period.43 
Normocytic/normochromic anemia is also often present.8,43 
Definitive diagnosis is established by DNA sequencing of 
the TNFRSF1A gene.47,52 Mutations are found in 32 to 50% 
of patients with a family history of TRAPS, and in less than 
10% of sporadic cases.53
The main complication of TRAPS is secondary amyloidosis 
progressing to renal failure.54 Patients with cysteine residue 
mutations have a 64% chance of developing amyloidosis, 
compared with 14% of affected patients as a whole.43 This 
greater risk may be associated with increased disease 
severity in this subgroup of TRAPS patients.
The TNF inhibitor etanercept (Enbrel®; recombinant 
soluble TNF receptor fusion protein, p75-TNFR-Fc), is the 
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Familial cold autoinflammatory syndrome (FCAS)
FCAS (OMIM accession no. 120100), also known as 
familial cold urticaria, is at the benign end of the CAPS 
spectrum, and has the most favorable prognosis of all the 
cryopyrinopathies.6,61,71 FCAS is characterized by episodes of 
low-grade fever (93%), polyarthralgia (96%), and nonpruritic 
pseudourticarial rash (100%) appearing 1-2 hours after 
cold exposure (range: 30 min to 6 h) and persisting for 
approximately 12 hours.7,71,72 Other commonly reported 
symptoms include conjunctivitis (84%), profuse sweating 
(78%), dizziness (67%), headache (58%), nausea (51%), 
and extreme thirst (53%).72 Symptoms are most intense in 
young adults, but may begin as early as childhood.73 Less 
commonly, the syndrome may present as recurrent fever, 
mild arthralgia, inflammatory cardiomyopathy, nephropathy, 
and thyroiditis, with no skin involvement.8,74 Secondary 
amyloidosis is the main cause of death, occurring in up 
to 2% of cases.28,75 Treatment includes prevention of cold 
exposure and, in more severe cases, anakinra.7,57 A recent 
study of rilonacept, a long-acting soluble receptor that binds 
IL-1, found good efficacy and safety in 44 patients with 
FCAS.76 NSAIDs and corticosteroids are variably effective, 
and antihistamines are not effective at all.70,77
Muckle-Wells syndrome (MWS)
In 1962, Muckle & Wells described a familial syndrome 
of urticaria, deafness, and amyloidosis affecting nine 
individuals.78 The symptoms of MWS (OMIM accession no. 
191100) arise in childhood, as an urticaria-like rash with low-
grade fever and arthralgia.8 Recurring episodes of arthritis 
and conjunctivitis may also occur.79 The most characteristic 
manifestation of MWS is sensorineural hearing loss, which is 
due to chronic inflammation of the organ of Corti with cochlear 
nerve atrophy.79 Less common findings include oral and 
genital ulcers, cystinuria, ichthyosis, recurrent abdominal 
pain, and microscopic hematuria.8,79 Secondary amyloidosis 
is common, and may occur in 1/3 to 1/4 of patients.6,75 
A finding of CIAS1 mutation confirms the diagnosis.18 Other 
laboratory findings include thrombocytopenia, anemia, and 
increased levels of acute-phase reactants.61,80 As in the other 
cryopyrinopathies, IL-1 receptor inhibition with anakinra 
can reverse the clinical manifestations of MWS, including 
hearing loss.57,80 A recent study of 33 MWS patients found 
good clinical and laboratory response to canakinumab, a 
human anti-IL-1beta monoclonal antibody.
Neonatal onset multisystem inflammatory disease/
chronic infantile neurologic, cutaneous, and articular 
syndrome (NOMID or CINCA syndrome)
NOMID, or CINCA syndrome (OMIM accession no. 
607115), is the most severe phenotype of the cryopyrinopathy 
spectrum, and was first described by Prieur & Griscelli in 
1981.82 The disease is characterized by a triad of rash, 
chronic aseptic meningitis, and arthropathy.69,82 Clinical 
manifestations arise in the first weeks of life; the cutaneous 
lesions often appear within hours of birth.69 Inflammatory 
symptoms (such as fever) are practically continuous, with 
occasional flares, and affected children have severe growth 
retardation.7,69,71
Skin lesions are found in nearly 100% of cases.69 CNS 
involvement is the second most common feature, typically 
presenting as chronic aseptic meningitis with leukocyte 
infiltration of the cerebrospinal fluid, which leads to a 
broad range of symptoms including chronic irritability, 
headaches, seizures, transient hemiplegia, and lower limb 
spasticity.69,70 If left untreated, approximately 80% of 
patients will develop sensorineural hearing loss and ocular 
disease, such as conjunctivitis, anterior and posterior 
uveitis, papilledema, and optic nerve atrophy with loss 
of vision.70,83 Other findings include developmental delay 
and mental retardation.8,83 Patients with NOMID/CINCA 
syndrome have a typical facial appearance, characterized by 
frontal bossing, macrocrania, and saddle nose.69,70 Figures 
2A and 2B show the characteristic facies of NOMID in three 
affected patients.
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Figure 2 - A) Characteristic facies (saddle nose) and urticaria-like rash of neonatal onset multisystem inflammatory 
disease; B) Characteristic facies (frontal bossing) in two patients with neonatal onset multisystem 
inflammatory disease
A B
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The musculoskeletal changes of NOMID/CINCA syndrome 
can range from asymptomatic arthritis to deforming 
arthropathy.8,83 Most patients show inflammatory changes 
of the long-bone epiphyses and metaphyses, with abnormal 
epiphyseal calcification and cartilage overgrowth, leading to 
shortened limbs and joint deformities. Premature ossification 
of the patella, with symmetrical patellar overgrowth, is 
a characteristic finding.69,71,84 The typical arthropathy of 
NOMID is found in 50% of patients.69
Nonspecific laboratory changes are as in other 
autoinflammatory syndromes, and may include anemia, 
thrombocytosis, moderately increased white blood cell 
counts, and increased inflammatory markers, such as ESR 
and CRP levels.8,69 The diagnosis of NOMID/CINCA syndrome 
relies on adequate clinical suspicion and confirmatory 
genetic testing.18 However, only 50% of patients with a 
characteristic presentation of NOMID/CINCA syndrome have 
CIAS1 mutations, which suggests that other yet-unknown 
genes may also be involved in its pathophysiology.69
Without early identification and treatment, the prognosis 
for patients with NOMID/CINCA syndrome is guarded. In 
addition to deforming articular involvement and neurologic 
sequelae, the disease carries a high risk of secondary 
amyloidosis in the few patients who live to adulthood.7,85
Anakinra, an IL-1 receptor antagonist, is currently the 
drug of choice for treatment of NOMID and has been widely 
used in this indication, providing significant improvement in 
all clinical manifestations of the disease and, consequently, 
patient quality of life.57,69 Anakinra is currently unavailable 
in Brazil, and other anti-IL1 agents have yet to reach the 
Brazilian market. Corticosteroids and NSAIDs can provide 
symptomatic relief, but have no effect on articular or 
neurologic involvement.8,69 Thalidomide has also been used 
in rare cases, with satisfactory results.86
Mevalonate kinase deficiency (MKD) or hyper-IgD 
and periodic fever syndrome (HIDS)
HIDS (OMIM accession no. 260920) follows an autosomal 
recessive pattern of inheritance, and is most often 
diagnosed in Northeastern Europe.87 The disease is caused 
by mutations in the MVK (mevalonate kinase) gene, which 
was discovered in 1999.87 Thus far, 108 HIDS-associated 
mutations have been discovered throughout the gene.18 
MVK, which has 11 exons and is located on the long arm 
of chromosome 12 (locus 12q24), codes for mevalonate 
kinase (MK), a 396-amino acid-long enzyme.87 Most patients 
have a combination of two mutations, one of which is very 
often V377I.87 HIDS-associated mutations lead to a major 
reduction in MK activity (1 to 10% of normal levels), whereas 
mutations that completely eliminate MK function lead to 
a condition known as mevalonic aciduria (MA).88,89 MA is 
a rare disease characterized by periodic fever with severe 
CNS involvement, mental retardation, ataxia, myopathy, 
poor growth, and early death.42,89
MK plays an essential role in the isoprenoid and 
cholesterol synthesis pathways.89 It catalyzes the conversion 
of mevalonic acid to mevalonate 5-phosphate during the 
synthesis of molecules such as cholesterol, vitamin D, 
biliary salts, corticosteroids, and non-steroidal isoprenoid 
compounds.42,89 During cholesterol biosynthesis, 3-hydroxy-
3-methylglutaryl-coenzyme A (HMG-CoA) reductase 
(the enzyme inhibited by statins) converts HMG-CoA to 
mevalonate, which is then phosphorylated to mevalonate 
phosphate.90 Mutations in the MVK gene block this pathway, 
preventing the conversion of mevalonate to mevalonate 
phosphate.91 The absence of a negative feedback loop, 
which is naturally provided by the presence of the end 
products of synthesis, leads to increased HMG-CoA reductase 
activity, consequently increasing serum, tissue, and urine 
levels of mevalonic acid. 92 In vitro studies have shown 
that reduced synthesis of isoprenoids is associated with 
increased production of IL1-beta.93 Another recent in vitro 
study showed that MK inhibition leads to increased secretion 
of IL1-beta due to activation of caspase-1, the enzyme that 
catalyzes formation of active IL1-beta from its precursor.94 
High levels of immunoglobulin D (IgD)31 are characteristic 
of HIDS, but are apparently not associated with the severity 
of pathophysiology of the condition. 95
In MKD, febrile attacks occur more frequently in the 
first year of life, lasting 3 to 7 days and recurring every 4 
to 6 weeks.8 However, the time elapsed between episodes 
can vary from patient to patient and even in a single 
individual.96 Febrile episodes recur for years, most frequently 
in childhood and adolescence, but months to years can 
go by between flares.96,97. Episodes may be triggered by 
immunization, trauma, surgery, or stress, and, in 76% of 
patients, are characterized by high fever preceded by chills.7,8 
Lymphadenopathy is extremely common (94%); it is usually 
cervical, bilateral, and painful.33,96 Abdominal pain is also 
a frequent symptom (72%), and may be accompanied by 
vomiting (56%) and/or diarrhea (82%).96,98 Patients will also 
frequently report headache (52%), and splenomegaly and 
hepatomegaly are common (the latter less so).96 Roughly 
80% of patients report polyarthralgia, and 68% have 
non-erosive arthritis of the large joints, particularly of the 
knees and ankles.8,96 Arthritis is usually polyarticular and 
symmetric.8,96 Over 82% of patients have diffuse cutaneous 
lesions, which may consist of erythematous maculopapular 
rash, urticaria-like rash, erythematous nodules, petechiae, 
or purpura.88,99 Rarely, patients may present with serositis 
or muscle pain, and a minority of patients has oral or vaginal 
ulcers.8 Progression to amyloidosis is exceedingly rare, and 
has only been described in four patients thus far.100-102 The 
first case of macrophage activation syndrome in a patient 
with MKD was also reported recently.103
Febrile episodes may be accompanied by sudden increase 
in acute phase reactant levels, including neutrophilic 
leukocytosis and elevated ESR, CRP, and SAA.6 Measurement 
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of urinary mevalonate levels during attacks may be useful, 
particularly in patients with normal IgD levels.90
IgD levels are persistently high (≥100 U/mL) in most 
patients, and over 80% of patients have concomitant increase 
in immunoglobulin A levels (≥260 mg/dL).90,104 Nonetheless, 
IgD levels may be within normal limits in some HIDS patients, 
especially children under the age of 3.8,95 Furthermore, the 
finding of high IgD levels is not specific for HIDS, as it occurs 
in other inflammatory diseases, such as FMF and TRAPS.95 
In these conditions, however, IgD levels never exceed 100 
U/mL, unlike in HIDS.6,95 The utility of high IgD levels in the 
diagnosis of MKD was established in a study of 50 patients 
with the MKD phenotype.95 The sensitivity and specificity 
of serum IgD measurement for the diagnosis of MKD were 
found to be 79 and 27% respectively, and the positive and 
negative predictive values were 50 and 58% respectively. 
In addition, five patients with MVK mutations were found 
to have normal immunoglobulin levels.95
The diagnosis of MKD is confirmed by a finding of 
MVK mutations.18 However, the presence of a clinical 
phenotype consistent with the disease in conjunction 
with high serum IgD and urinary mevalonate levels may 
suggest the diagnosis.6,95 To support diagnostic efforts, a 
clinical criterion has been developed for MKD screening in 
patients with recurrent fever.105 The authors proposed that 
genetic screening for MKD in patients with recurrent fever 
be performed only in those patients younger than 5 years 
at disease onset or those with joint pain and periodic fever 
attacks lasting fewer than 14 days. Use of these criteria 
would avoid unnecessary molecular testing.105
Most of the usual treatments, such as NSAIDs, 
corticosteroids, IVIG, colchicine, and thalidomide, are 
ineffective in HIDS.28 The involvement of MK in the cholesterol 
synthesis pathway has encouraged the introduction of statins 
in the management of MKD; the efficacy of simvastatin, 
an HMG-CoA reductase inhibitor, has been demonstrated 
in 5/6 of MKD patients.106 Use of etanercept and anakinra 
in refractory cases has also been reported.107-113
Pediatric granulomatous arthritis (PGA)
The term PGA (OMIM accession no. 186580) is applied to 
two distinct conditions with a similar clinical phenotype: Blau 
syndrome, a familial disorder, and early onset sarcoidosis, a 
sporadic condition.114 PGA follows an autosomal dominant 
pattern of inheritance and is caused by mutations in the 
NOD2 gene, also known as CARD15, located on chromosome 
16.18 This gene codes for the NOD2 protein, a member of 
the NOD-LRR family of pattern recognition receptors that 
bears a strong structural similarity to cryopyrin.42,115
NOD2 mutations are found in 50 to 90% of patients with 
the classic triad of arthritis, dermatitis, and uveitis.116 Thus 
far, 15 PGA-related mutations have been described, most 
mapped to the NOD domain.18 Interestingly, mutations in the 
leucine-rich repeats (LRR) domain of NOD2 are associated 
with Crohn’s disease.18,117 NOD2 is considered a sort of 
cytoplasmic sensor for detection of pathogen components, 
playing a role similar to that of toll-like receptors; NOD2 
stimulation may lead to activation of the NF-κB and mitogen-
activated protein kinase (MAPK) pathways, triggering 
production of cytokines involved in innate immune response, 
such as IL-1β and the defensins.42
PGA is characterized by chronic granulomatous 
inflammation of the eyes, joints and skin; onset usually 
precedes the fourth year of life.118 Arthritis is universal; it 
is polyarticular in 96% of patients and oligoarticular in the 
remaining 4%.116 Around 40% of patients have hypertrophic 
tenosynovitis, and articular involvement is symmetric in 
most cases.116 Ocular involvement is found in 84% of 
patients, and follows a chronic, persistent course in the 
vast majority of cases.116 Approximately 25% of affected 
individuals have anterior or intermediate uveitis, and 50% 
have panuveitis; uveitis is bilateral in most patients.116,117 
Fifty percent of patients develop cataracts, whereas 30% 
develop glaucoma and 40% go on to have severe visual 
impairment.116 The typical rash of PGA is described as 
brown in color and ichthyosis-like, and is found in 88% 
of patients.116,117 Less common findings include fever, 
camptodactyly, and cranial neuropathy.114 Figure 3 shows 
a patient with PGA and ichthyosiform rash.
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Figure 3 - Ichthyosiform rash in a patient with early onset 
sarcoidosis
Laboratory testing may reveal persistent leukocytosis, 
thrombocytosis, and increased ESR and CRP levels.116 
Non-caseous granulomas may be found in the synovial 
tissue, skin, and liver.116,117 Definitive diagnosis can only 
be established by a finding of NOD2 mutation.18
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Treatment is NSAID-based in patients with mild disease, 
whereas more severe manifestations require systemic 
corticosteroid therapy.7,119 Other agents used in the 
treatment of PGA include methotrexate and ciclosporin, and 
the use of biologicals (etanercept, infliximab, and anakinra) 
has been reported, particularly in patients with refractory 
ocular involvement.7,117,119
Pyogenic aseptic arthritis, pyoderma gangrenosum, 
and acne syndrome (PAPA syndrome)
PAPA syndrome (OMIM accession no. 604416) is an 
autosomal dominant disease characterized by sterile, 
deforming arthritis, skin ulcers (pyoderma gangrenosum), 
and severe cystic acne.42,120 Unlike other autoinflammatory 
syndromes, PAPA does not have fever as its most prominent 
symptom.42
PAPA syndrome is caused by mutations in the gene that 
codes proline-serine-threonine phosphatase interacting 
protein 1 (PSTPIP1), and only five associated mutations 
have been reported thus far.18 PSTPIP1 is a 416-amino acid-
long protein expressed mostly in neutrophils.42 Mutations 
in PSTPIP1 are believed to lead to hyperphosphorylation of 
the protein, which could increase the potency of its binding 
to pyrin, with subsequent activation of IL-1β production, 
as seen in FMF.121
Majeed syndrome
Majeed syndrome (OMIM accession no. 146462), 
like PAPA syndrome, is considered a Pyogenic AIS, but 
is inherited in an autosomal recessive pattern.122 It is 
caused by mutations in the LPIN2 gene, which codes for 
an eponymous protein.123 Thus far, only nine associated 
mutations have been described.18
Patients with Majeed syndrome present with early (mostly 
neonatal) onset of chronic recurrent multifocal osteomyelitis, 
neutrophilic dermatitis, and congenital dyserythropoietic 
anemia.124 Cutaneous involvement is characterized by 
pustular dermatitis, although psoriasis-like lesions have 
been described.7,124 The osteomyelitis of Majeed syndrome 
may affect the clavicles, sternum, long bones, and, less 
commonly, the jaw or vertebrae.122,125 Bone biopsy reveals 
nonspecific granulocytic infiltration.123,125
Antibiotics are of no use in the treatment of Majeed 
syndrome.7,125 Some patients may benefit from therapy 
with NSAIDs, corticosteroids, interferon gamma, 
bisphosphonates, and anti-TNF agents.7
Deficiency of interleukin-1–receptor antagonist 
(DIRA)
A new autosomal recessive AIS, caused by mutations 
in the IL1RN gene, which codes for interleukin-1 receptor 
antagonist (IL1Ra), was reported recently.126 The syndrome, 
which was described in 10 patients, was given the name 
“deficiency of interleukin-1 receptor antagonist” (DIRA) 
and is characterized by early onset of symptoms, most 
frequently in the neonatal period.126,127
Patients with DIRA present with pustulosis, multifocal 
aseptic osteomyelitis, and markedly elevated ESR and 
CRP levels.126,127 Skin involvement may range from sparse 
pustules to generalized pustular dermatitis or ichthyosiform 
lesions.126 Skin biopsy may reveal neutrophilic infiltration 
of the epidermis and dermis, pustules in the stratum 
corneum, acanthosis, and hyperkeratosis.126 All patients 
described in the report had osteomyelitis, characterized by 
pain with movement and periarticular swelling; the most 
frequent radiological findings were widening of the costal 
arches, periosteal elevation along long bones, and multifocal 
osteolytic lesions.126,127
As in the other Pyogenic autoinflammatory syndromes 
(PAPA and Majeed syndrome), fever is not a striking 
feature of DIRA, and was not present in any of the patients 
described.126,127 Two of the 10 patients had interstitial 
lung disease, and three died before therapy could be 
attempted (at 2 months, 21 months, and 9 years of age 
respectively).126,127
The treatment of choice is recombinant IL-1RA 
(anakinra), which produces a dramatic response in skin 
and bone symptoms and in the quality of life of patients 
with DIRA.126
Final considerations
The past decade has witnessed major advances in our 
understanding of the pathophysiology and clinical features 
of autoinflammatory syndromes.1 The periodic fever induced 
by these disorders must be distinguished from the fever 
caused by self-limited infections in healthy children, that 
caused by recurring infections in immunocompromised 
patients, and the fever of autoimmune disease.9,10
The recurring fever of AIS is not accompanied by 
respiratory symptoms and is unresponsive to antibiotics, 
which are often prescribed.10 Furthermore, most children with 
autoinflammatory syndromes have good growth, unlike most 
of those with primary of secondary immunodeficiencies.10 In 
addition, no specific antibodies associated with autoimmune 
disease are detectable, as self-reactive T cells and circulating 
autoantibodies are not involved in the pathophysiology of 
AIS.6,10 The signs and symptoms presented in Tables 2 
and 3 may be useful diagnostic red flags for suggesting or 
excluding the diagnosis of AIS.
Pediatricians must recognize the main clinical 
manifestations of the most prevalent autoinflammatory 
syndromes, as rheumatology referral can be the key to 
early diagnosis and treatment. Follow-up of patients with 
these syndromes must include assessment and prevention 
of the risk of amyloidosis (the foremost complication of the 
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majority of AIS) and genetic counseling. Specific therapies, 
such as IL-1 antagonists (IL-1 being the main cytokine 
involved in the pathogenesis of inflammatory symptoms in 
most AIS patients), have yet to become available in Brazil. 
Increased recognition of autoinflammatory syndromes in the 
country may provide a useful push for making these drugs 
available to Brazilian patients, which would significantly 
improve morbidity and mortality, particularly in early-onset 
syndromes and those associated with major impact on 
quality of life.
More recently, we have established a Brazilian working 
group, with international involvement, for clinical and 
genetic diagnosis of the most important AIS in the pediatric 
population. Brazil is a highly multiracial country and 
autoinflammatory syndromes may be underdiagnosed; 
proper recognition of these conditions is essential for 
individualized treatment.43,71,128,129
Conclusions
The autoinflammatory syndromes are caused by 
monogenic defects of innate immunity and are characterized 
Hereditary autoinflammatory syndromes - Jesus AA et al.
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